Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

I’m Diane Brady. From transformative weight loss treatment to a potential blockbuster for Alzheimer's, Dave Ricks of Eli ...

BioCrossroads has named Eli Lilly CEO, Dave Ricks, the recipient of the 2024 August M. Watanabe Life Sciences Champion of the ...

But earnings in the new range would still wind up being more than twice what the company registered for 2023. Shares of Indianapolis-based Eli Lilly and Co. were down 6%, or $57.02, to $846.56 in ...

Please go ahead. Thank you, Paul, and good morning, everybody. Thanks for joining us for Eli Lilly and company's Q3 2024 earnings call. I'm Joe Fletcher, Senior Vice President of Investor Relations.

Please go ahead. Thank you, Paul, and good morning, everybody. Thanks for joining us for Eli Lilly and Company's Q3 2024 earnings call. I'm Joe Fletcher, Senior Vice President of Investor Relations.

Eli Lilly and Company reported third quarter results and missed expectations and had to lower its guidance, which was a huge disappointment for investors. But in the last few years, Eli Lilly was ...

Skyrocketing demand for injectable weight loss and diabetes drugs has forced both Eli Lilly and its main rival, Novo Nordisk, to invest billions to increase manufacturing capacity. The company's ...

Eli Lilly executives insisted that underlying demand for the medicines remained strong and that the company has enough supply available. The reason for the disappointing sales, according to the ...